AstraZeneca and Hutchmed Report Positive Results from Lung Cancer Trial
AstraZeneca (AZN) and Hutchmed (HCM) announced positive results from a late-stage clinical trial for their jointly developed tyrosine kinase inhibitor, Orpathys. The drug met its primary endpoint when used in combination with AstraZeneca’s Tagrisso as first-line therapy for lung cancer patients. The successful outcome of the trial could support regulatory submissions and potentially expand treatment options for non-small cell lung cancer (NSCLC) patients who harbor specific genetic mutations, such as EGFR. This development is significant given the growing demand for targeted therapies in oncology. Both companies have a long-standing collaboration focused on developing innovative treatments for various cancers.
